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Clinical PerspectiveWhat Is New?Aprotinin is currently being reestablished into clinical practice in Europe and Canada for adult patients undergoing isolated coronary bypass surgery without any new clinical trials on safety in this subgroup.The present analysis on a selected low‐risk coronary bypass surgery population supports the association between aprotinin administration and adverse hospital outcomes and long‐term survival.What Are the Clinical Implications?On the basis of the present findings, a word of caution should be exercised by local authorities on the liberal use of aprotinin before further investigations will clarify the potential risks related to its perioperative administration.

Introduction {#jah32950-sec-0009}
============

Bleeding remains a major complication after coronary artery bypass graft (CABG) surgery and is associated with poorer short‐ and long‐term outcomes.[1](#jah32950-bib-0001){ref-type="ref"} Aprotinin is the most studied antifibrinolytic agent to limit blood loss in cardiac surgery. However, concerns have been expressed over its potential detrimental effect on short‐term outcomes, including renal dysfunction, graft occlusion, and stroke,[2](#jah32950-bib-0002){ref-type="ref"}, [3](#jah32950-bib-0003){ref-type="ref"}, [4](#jah32950-bib-0004){ref-type="ref"}, [5](#jah32950-bib-0005){ref-type="ref"} as well as late mortality.[6](#jah32950-bib-0006){ref-type="ref"} Aprotinin was taken off the market in November 2007 because of safety concerns expressed in 4 studies in *The New England Journal of Medicine*.[2](#jah32950-bib-0002){ref-type="ref"}, [3](#jah32950-bib-0003){ref-type="ref"}, [4](#jah32950-bib-0004){ref-type="ref"}, [5](#jah32950-bib-0005){ref-type="ref"} Ten years later, aprotinin is being reintroduced, but without any new clinical trials on safety. The regulatory authorities, including Health Canada and the European Medicines Agency, revisited the previously available data, and after highlighting several methodological limitations, they concluded that no firm assumption could be made on mortality.[7](#jah32950-bib-0007){ref-type="ref"} Consequently, aprotinin is currently being reestablished into clinical practice in Europe and Canada for adult patients undergoing isolated CABG who are at high risk of major blood loss.[8](#jah32950-bib-0008){ref-type="ref"}

The ART (Arterial Revascularization Trial) is designed to compare 10‐year survival after bilateral internal thoracic artery versus single left internal thoracic artery grafting, and an interim report at 5 years has not shown any clear difference between the 2 groups.[9](#jah32950-bib-0009){ref-type="ref"} Approximately 30% of patients enrolled in the ART received perioperative aprotinin. We investigated the association between perioperative aprotinin administration and short‐ and long‐term outcomes in patients undergoing isolated CABG by conducting a post hoc analysis on high‐quality data from the ART.

Methods {#jah32950-sec-0010}
=======

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. A post hoc analysis of the ART was conducted. This research adheres to the principles set forth in the Declaration of Helsinki. In ART, aprotinin was the only antifibrinolytic agent administered perioperatively, and its use was based on surgeon discretion/local policies. For the present analysis, among patients enrolled in the ART (n=3102) from 2004 to 2007, we excluded those who did not undergo surgery (n=18) and those with no information about use of perioperative aprotinin (n=9). Perioperative aprotinin was administered to 836 of 3076 patients (27.1%, aprotinin group) included in the present analysis. The baseline characteristics in the aprotinin and no aprotinin groups are reported in Table [S1](#jah32950-sup-0001){ref-type="supplementary-material"}. There was a large variation in aprotinin use across different centers. Unadjusted hospital and long‐term outcomes in the 2 groups are reported in Tables [S2](#jah32950-sup-0001){ref-type="supplementary-material"} and [S3](#jah32950-sup-0001){ref-type="supplementary-material"}.

Patient Involvement {#jah32950-sec-0011}
-------------------

Because the present study represents a post hoc observational analysis of the ART, there was no patient involvement.

Trial Design {#jah32950-sec-0012}
------------

The ART was approved by the institutional review board of all participating centers, and informed consent was obtained from each participant. The protocol for the ART has been published.[10](#jah32950-bib-0010){ref-type="ref"} Briefly, the ART is a 2‐arm, randomized, multicenter trial conducted in 28 hospitals in 7 countries, with patients being randomized equally to single left internal thoracic artery or bilateral internal thoracic artery grafts. Eligible patients were those with multivessel coronary artery disease undergoing CABG, including urgent patients. Only emergency patients (refractory myocardial ischemia/cardiogenic shock) and those requiring single grafts or redo CABG were excluded.

Follow‐Up {#jah32950-sec-0013}
---------

Questionnaires were sent to study participants by post every year after surgery. No clinic visits were planned apart from the routine clinical 6‐week postoperative visit. Participants were sent stamped addressed envelopes to improve the return rates of postal questionnaires. Study coordinators contacted participants by telephone to alert them to the questionnaire\'s arrival and to ask them about medications, adverse events, and health services resource use.

Study Outcomes {#jah32950-sec-0014}
--------------

Primary outcomes were hospital outcomes, which included hospital death, myocardial infarction (MI), cerebrovascular accident, need for repeated revascularization, postoperative atrial fibrillation, need for intra‐aortic balloon pump insertion, postoperative renal replacement therapy, acute kidney injury (AKI), sternal wound infection, red blood cell transfusion, and reexploration for bleeding. We also investigated the association between perioperative aprotinin administration and 5‐year mortality (including all‐cause and cardiovascular mortality), nonfatal MI, cerebrovascular accident, and repeated revascularization.

Outcome Definitions {#jah32950-sec-0015}
-------------------

Death was classified into cardiovascular and noncardiovascular, where possible, using autopsy reports and death certificates. Congestive heart failure, arrhythmia or MI, pulmonary embolus, and dissection were considered cardiovascular causes of death.

MI was diagnosed when 2 of the following 3 criteria were present: (1) unequivocal ECG changes, (2) elevation of cardiac enzyme(s) above twice the upper limit of normal or diagnostic troponin increases, and (3) chest pain typical for acute MI, which lasted \>20 minutes. Cerebrovascular accident was defined as new neurological deficit evidenced by clinical signs of paresis, plegia, or new cognitive dysfunction, including any mental status alteration lasting \>24 hours and/or evidence on computed tomographic or magnetic resonance imaging scan of a recent brain infarct (\<6 months). Repeated revascularization was defined as coronary bypass surgery or percutaneous coronary intervention performed after the trial procedure. AKI was defined as a 0.3‐mg/dL (≥26.5‐mmol/L) creatinine increase from baseline within 48 hours of surgery.[11](#jah32950-bib-0011){ref-type="ref"}

Statistical Analysis {#jah32950-sec-0016}
--------------------

Multiple imputation (m=10) was used to address missing data (Figure [S1](#jah32950-sup-0001){ref-type="supplementary-material"}). The method of Rubin[12](#jah32950-bib-0012){ref-type="ref"} was used to combine results from each of the imputed data sets (Amelia R package). Because use of aprotinin was not based on randomization, a propensity score (PS) was generated for each patient from a multivariable logistic regression model on the basis of baseline and intraoperative covariates as independent variables, with aprotinin versus no aprotinin as a binary dependent variable.[13](#jah32950-bib-0013){ref-type="ref"} Because a large variation in aprotinin use was found among recruiting centers, individual centers were also included into the PS model to adjust for potential confounding related to different practice patterns. Pairs of patients were derived using greedy 1:1 matching, with a caliper of width of 0.2 SDs of the logit of the PS (MatchIt R package). The quality of the match was assessed by graphical visualization of PS distribution overlapping. Selected pretreatment variables in PS--matched groups were compared using the absolute standardized mean difference, with a value \>0.10 taken to represent meaningful covariate imbalance. For outcomes analysis, conditional logistic and Cox regression models stratified for matched pairs with robust standard error estimation were used to investigate the treatment effect on short‐ and long‐term outcomes, respectively. For competing risks, a model for the subdistribution hazard of the cumulative incidence function, proposed by Fine and Gray, was used[14](#jah32950-bib-0014){ref-type="ref"} (riskRegression R packages). The effect of aprotinin on long‐term mortality was also adjusted for medications prescribed at discharge. *P*\<0.05 was considered statistically significant. All statistical analysis was performed using R Statistical Software (version 3.2.3; R Foundation for Statistical Computing, Vienna, Austria).

Results {#jah32950-sec-0017}
=======

PS Matching {#jah32950-sec-0018}
-----------

Table [S2](#jah32950-sup-0001){ref-type="supplementary-material"} summarizes baseline characteristics of patients in the original aprotinin and no aprotinin groups. Patients who received aprotinin were more likely to be white, to be older, and to have an advanced New York Heart Association functional class. The use of aprotinin was also associated with a higher rate of preoperative dual‐antiplatelet administration and use of cardiopulmonary bypass and saphenous vein grafts. Patients who did not receive aprotinin were more likely to be diabetic and to receive preoperative angiotensin‐converting enzyme inhibitors/receptor blockers. There were also a few centers where the aprotinin administration rate was extremely high (eg, Edinburgh Royal Infirmary) and others where the aprotinin administration rate was extremely low (eg, Papworth Hospital and Austin Repatriation Medical Centre). PS matching selected 536 matched pairs with similar distribution of covariates and recruiting centers (all standardized mean differences, \<0.10), as shown in Table [1](#jah32950-tbl-0001){ref-type="table-wrap"}, and comparable PS distribution (Figure [1](#jah32950-fig-0001){ref-type="fig"}).

###### 

Baseline Characteristics of Patients in the Aprotinin and No Aprotinin Groups (Matched Sample)

  Characteristics                             Aprotinin Group (n=536)   No Aprotinin Group (n=536)   SMD
  ------------------------------------------- ------------------------- ---------------------------- ---------
  Ethnicity                                                                                          0.221
   White                                      518 (96.6)                522 (97.4)                   
   East Asian                                 3 (0.6)                   0 (0.0)                      
   South Asian                                15 (2.8)                  7 (1.3)                      
   Afro‐Caribbean                             0 (0.0)                   0 (0.0)                      
   African                                    0 (0.0)                   1 (0.2)                      
   Other                                      0 (0.0)                   6 (1.1)                      
  Age, mean (SD), y                           64.76 (9.15)              64.51 (8.56)                 0.028
  Female sex                                  81 (15.1)                 71 (13.2)                    0.054
  BMI, mean (SD), kg/m^2^                     28.10 (3.99)              28.24 (4.06)                 0.034
  Creatinine, mean (SD), mmol/L               96.28 (21.86)             95.84 (21.46)                0.020
  NYHA class III/IV                           103 (19.2)                98 (18.3)                    0.024
  Unstable angina                             40 (7.5)                  39 (7.3)                     0.007
  Diabetes mellitus                                                                                  0.042
   No history of diabetes mellitus            426 (79.5)                417 (77.8)                   
   Insulin‐dependent diabetes mellitus        23 (4.3)                  26 (4.9)                     
   Non--insulin‐dependent diabetes mellitus   87 (16.2)                 93 (17.4)                    
  Smoking                                                                                            0.100
   Current smoker                             91 (17.0)                 87 (16.2)                    
   Ex‐smoker                                  294 (54.9)                319 (59.5)                   
   Never smoked                               151 (28.2)                130 (24.3)                   
  COPD/asthma                                 37 (6.9)                  34 (6.3)                     0.023
  PVD                                         35 (6.5)                  41 (7.6)                     0.044
  CVA                                         19 (3.5)                  19 (3.5)                     \<0.001
  MI                                          242 (45.1)                243 (45.3)                   0.004
  PCI                                         95 (17.7)                 92 (17.2)                    0.015
  AF                                          10 (1.9)                  9 (1.7)                      0.014
  LVEF                                                                                               0.031
   Good (≥50%)                                423 (78.9)                418 (78.0)                   
   Moderate (31%--49%)                        104 (19.4)                110 (20.5)                   
   Poor (≤30%)                                9 (1.7)                   8 (1.5)                      
  Antiplatelet regimen                                                                               0.038
   None                                       78 (14.6)                 76 (14.2)                    
   Aspirin only                               313 (58.4)                321 (59.9)                   
   Aspirin plus clopidogrel                   124 (23.1)                121 (22.6)                   
   Clopidogrel only                           21 (3.9)                  18 (3.4)                     
  Antiplatelet within 3 d                     116 (21.6)                117 (21.8)                   0.005
  Warfarin                                    10 (1.9)                  10 (1.9)                     \<0.001
  β‐Blockers                                  443 (82.6)                448 (83.6)                   0.025
  Statins                                     510 (95.1)                515 (96.1)                   0.046
  ACEI/ARB                                    358 (66.8)                346 (64.6)                   0.047
  Off‐pump surgery                            173 (32.3)                188 (35.1)                   0.059
  Use of saphenous vein graft                 439 (81.9)                448 (83.6)                   0.044
  No. of grafts, mean (SD)                    3.17 (0.81)               3.20 (0.81)                  0.030
  Hospital                                                                                           0.08
   First Department of Cardiac Surgery        66 (12.3)                 68 (12.7)                    
   Second Department of Cardiac Surgery       46 (8.6)                  44 (8.2)                     
   Austin Repatriation Medical Centre         10 (1.9)                  7 (1.3)                      
   Bydgoszcz Szpital Uniwersytecki            0 (0.0)                   0 (0.0)                      
   Care Hospital                              0 (0.0)                   1 (0.2)                      
   Castle Hill Hospital                       39 (7.3)                  34 (6.3)                     
   Edinburgh Royal Infirmary                  30 (5.6)                  22 (4.1)                     
   Escorts Heart Institute                    0 (0.0)                   0 (0.0)                      
   Freeman Hospital                           0 (0.0)                   1 (0.2)                      
   Glenfield Hospital                         38 (7.1)                  38 (7.1)                     
   Harefield Hospital                         28 (5.2)                  25 (4.7)                     
   Heart Institute of Pernambuco              0 (0.0)                   2 (0.4)                      
   John Paul Hospital                         0 (0.0)                   1 (0.2)                      
   John Radcliffe Hospital                    100 (18.7)                113 (21.1)                   
   King\'s College Hospital                   0 (0.0)                   0 (0.0)                      
   Landesklinikum St Polten                   6 (1.1)                   2 (0.4)                      
   Manchester Royal Infirmary                 23 (4.3)                  31 (5.8)                     
   Medical University of Gdansk               3 (0.6)                   3 (0.6)                      
   Northern General Hospital                  10 (1.9)                  10 (1.9)                     
   Ospedale Mauriziano                        0 (0.0)                   0 (0.0)                      
   Papworth Hospital                          2 (0.4)                   4 (0.7)                      
   Royal Brompton Hospital                    25 (4.7)                  24 (4.5)                     
   Royal Sussex County Hospital               50 (9.3)                  58 (10.8)                    
   Rzeszow Szpital Wojewodzki 2               2 (0.4)                   2 (0.4)                      
   Silesian Centre for Heart Disease          0 (0.0)                   0 (0.0)                      
   St George\'s Hospital                      0 (0.0)                   1 (0.2)                      
   The Cardiothoracic Centre                  0 (0.0)                   0 (0.0)                      
   University Hospital of Wales               58 (10.8)                 45 (8.4)                     

Data are given as number (percentage) unless otherwise indicated. ACEI/ARB indicates angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker; AF, atrial fibrillation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; and SMD, standardized mean difference.

![Mirrored histogram showing propensity score (PS) distribution in the 2 groups before (white) and after (red and blue) matching.](JAH3-7-e007570-g001){#jah32950-fig-0001}

Hospital Outcomes {#jah32950-sec-0019}
-----------------

Hospital outcomes in the matched sample are summarized in Table [2](#jah32950-tbl-0002){ref-type="table-wrap"}. Hospital mortality was significantly higher in the aprotinin group (9 \[1.7%\] versus 1 \[0.2%\]; odds ratio \[OR\], 9.12; 95% confidence interval \[CI\], 1.15--72.2; *P*=0.03). Aprotinin was also associated with an increased risk of intra‐aortic balloon pump insertion (37 \[6.9%\] versus 17 \[3.2%\]; OR, 2.26; 95% CI, 1.26--4.07; *P*=0.006) and AKI (102 \[19.0%\] versus 76 \[14.2%\]; OR, 1.42; 95% CI, 1.03--1.97; *P*=0.03), although the increased risk of renal replacement therapy in the aprotinin group did not reach statistical significance (25 \[4.7%\] versus 18 \[3.4%\]; OR, 1.41; 95% CI, 0.75--2.61; *P*=0.27). We also found a nonsignificant trend toward increased risk of in‐hospital repeated revascularization in the aprotinin group (7 \[1.3%\] versus 2 \[0.4%\]; OR, 3.53; 95% CI, 0.73--17.1; *P*=0.1). Aprotinin was not associated with a lower incidence of red blood cell transfusion (37 \[6.9%\] versus 28 \[5.2%\]; OR, 1.34; 95% CI, 0.81--2.23; *P*=0.25) or reexploration for bleeding (26 \[4.9%\] versus 19 \[3.5%\]; OR, 1.39; 95% CI, 0.76--2.53; *P*=0.28).

###### 

Hospital Outcomes in the Matched Sample

  Outcomes                     Aprotinin Group (n=536)   No Aprotinin Group (n=536)   *P* Value   OR (95% CI)
  ---------------------------- ------------------------- ---------------------------- ----------- -------------------
  Mortality                    9 (1.7)                   1 (0.2)                      0.03        9.12 (1.15--72.2)
  MI                           12 (2.2)                  9 (1.7)                      0.51        1.34 (0.56--3.21)
  CVA                          8 (1.5)                   8 (1.5)                      1.00        1 (0.37--2.68)
  Repeated revascularization   7 (1.3)                   2 (0.4)                      0.11        3.53 (0.73--17.1)
  POAF                         143 (26.7)                169 (31.5)                   0.09        0.79 (0.61--1.03)
  IABP insertion               37 (6.9)                  17 (3.2)                     0.006       2.26 (1.26--4.07)
  RRT                          25 (4.7)                  18 (3.4)                     0.27        1.41 (0.75--2.61)
  AKI                          102 (19.0)                76 (14.2)                    0.03        1.42 (1.03--1.97)
  Sternal wound infection      25 (4.7)                  19 (3.5)                     0.35        1.33 (0.72--2.44)
  RBC transfusion              37 (6.9)                  28 (5.2)                     0.25        1.34 (0.81--2.23)
  Reexploration                26 (4.9)                  19 (3.5)                     0.28        1.39 (0.76--2.53)

Data are given as number (percentage) unless otherwise indicated. AKI indicates acute kidney injury; CI, confidence interval; CVA, cerebrovascular accident; IABP, intra‐aortic balloon pump; MI, myocardial infarction; OR, odds radio; POAF, postoperative atrial fibrillation; RBC, red blood cell; and RRT, renal replacement therapy.

Five‐Year Outcomes {#jah32950-sec-0020}
------------------

Five‐year outcomes are summarized in Table [3](#jah32950-tbl-0003){ref-type="table-wrap"} and Figures [2](#jah32950-fig-0002){ref-type="fig"} and [3](#jah32950-fig-0003){ref-type="fig"}. All‐cause mortality was significantly increased in the aprotinin group (56 \[10.6%\] versus 38 \[7.3%\]; hazard ratio, 1.51; 95% CI, 1.0--2.28; *P*=0.045). We found an excess of cardiovascular deaths, MIs, and repeated revascularizations in the aprotinin group, although these differences did not reach statistical significance. Medications at discharge were comparable between the 2 groups (Table [4](#jah32950-tbl-0004){ref-type="table-wrap"}). After controlling for medication at discharge, aprotinin remained associated with a significantly increased risk of late death (hazard ratio, 1.54; 95% CI, 1.02--2.33; *P*=0.04).

###### 

Five‐Year Outcomes in the Matched Sample

  Outcomes                     Aprotinin Group (n=536)   No Aprotinin Group (n=536)   *P* Value   HR (95% CI)
  ---------------------------- ------------------------- ---------------------------- ----------- -------------------
  Cardiovascular mortality     22 (4.1)                  18 (3.4)                     0.48        1.25 (0.67--2.33)
  MI                           18 (3.4)                  15 (2.8)                     0.58        1.21 (0.61--2.4)
  CVA                          12 (2.3)                  19 (3.6)                     0.23        0.64 (0.31--1.32)
  Repeated revascularization   37 (7.0)                  32 (6.1)                     0.49        1.18 (0.74--1.9)
  All‐cause mortality          56 (10.6)                 38 (7.3)                     0.045       1.51 (1.0--2.28)

Data are given as number (percentage) unless otherwise indicated. CI indicates confidence interval; CVA, cerebrovascular accident; HR, hazard ratio; and MI, myocardial infarction.

![Five‐year cumulative incidence of all‐cause mortality in the matched groups.](JAH3-7-e007570-g002){#jah32950-fig-0002}

![Five‐year cumulative incidence of cardiovascular (CV) death, myocardial infarction (MI), cerebrovascular accident (CVA), and repeated revascularization in the matched groups.](JAH3-7-e007570-g003){#jah32950-fig-0003}

###### 

Medication at Discharge in the Matched Sample

  Medications                 Aprotinin Group (n=536)   No Aprotinin Group (n=536)   *P* Value
  --------------------------- ------------------------- ---------------------------- -----------
  β‐Blocker                   462 (86.2)                450 (84.0)                   0.34
  Statins                     509 (95.0)                514 (95.9)                   0.55
  ACEI/ARB                    307 (57.3)                296 (55.2)                   0.53
  Antiplatelet regimen                                                               0.67
   None                       8 (1.5)                   11 (2.1)                     
   Aspirin only               416 (77.6)                417 (77.8)                   
   Aspirin plus clopidogrel   92 (17.2)                 94 (17.5)                    
   Clopidogrel only           20 (3.7)                  14 (2.6)                     
  Warfarin                    18 (3.4)                  23 (4.3)                     0.52

Data are given as number (percentage) unless otherwise indicated. ACEI/ARB indicates angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker.

Discussion {#jah32950-sec-0021}
==========

The present post hoc ART analysis found that, in patients undergoing isolated CABG, aprotinin administration was associated with a higher risk of in‐hospital mortality, intra‐aortic balloon pump insertion, and AKI. We also found a nonstatistically significant increased risk of early reintervention. At 5 years, perioperative aprotinin administration was associated with significantly higher mortality.

Aprotinin has been shown to effectively reduce blood loss and the need for transfusion associated with heart surgery[15](#jah32950-bib-0015){ref-type="ref"}; currently, Health Canada and the European Medicines Agency believe the accumulated evidence on the benefits of aprotinin outweighs its risks in isolated CABG surgery.[7](#jah32950-bib-0007){ref-type="ref"}, [8](#jah32950-bib-0008){ref-type="ref"} In a prospective cohort study in 2006, Mangano and colleagues[2](#jah32950-bib-0002){ref-type="ref"} reported that aprotinin was associated with an increased risk of renal failure, MI, heart failure, stroke, encephalopathy, and mortality (2.8% versus 1.3%; *P*=0.02). Consequently, in 2006, the Food and Drug Administration listed renal dysfunction, along with anaphylaxis, graft occlusion, and stroke, among the drug\'s safety concerns.[16](#jah32950-bib-0016){ref-type="ref"} However, the association between aprotinin and renal failure was disputed by Furnary and colleagues in 2007, who suggested that this was a confounding variable because renal impairment was also related to an increased packed red cell transfusion in the setting of cardiac surgery.[17](#jah32950-bib-0017){ref-type="ref"} In 2007, Mangano and colleagues reanalyzed the 2006 data and reported that aprotinin was independently predictive of 5‐year mortality.[6](#jah32950-bib-0006){ref-type="ref"} A possible limitation of this analysis was that the authors failed to report whether the surgery was on or off pump, and this variable may have influenced not only the choice of antifibrinolytic agent but also clinical outcomes. The Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration reviewed the evidence from these studies; the committee could not endorse the findings after questions about the methods used, and because the data had not been independently reviewed by the Food and Drug Administration.[18](#jah32950-bib-0018){ref-type="ref"}

Another source of concern about aprotinin\'s safety was a preliminary report in 2006, from the manufacturer\'s own database, that showed a higher risk of death and acute renal failure in patients undergoing CABG who received aprotinin compared with patients who had received other antifibrinolytics.[19](#jah32950-bib-0019){ref-type="ref"} This study was limited by its inability to account for the proportion of patients undergoing long‐term dialysis when assessing the need for postoperative dialysis. The BART (Blood Conservation Using Antifibrinolytics in a Randomized Trial), published in 2008,[5](#jah32950-bib-0005){ref-type="ref"} was a blinded randomized controlled trial comparing aprotinin, tranexamic acid, and aminocaproic acid in patients undergoing high‐risk cardiac surgery. The trial was terminated early on the advice of the safety committee because of a nonsignificant increase in mortality associated with aprotinin. Although the BART had the benefit of being a blinded randomized controlled trial, several limitations were identified in its conduct, in particular the unexplained exclusion of 137 patients from the analysis after randomization.[20](#jah32950-bib-0020){ref-type="ref"} In view of conflicting findings reported, further analyses based on high‐quality data are warranted to provide further evidence on the safety of perioperative aprotinin administration.

The present post hoc ART analysis found that aprotinin administration was significantly associated with an increased risk of hospital death, AKI, and need for intra‐aortic balloon pump insertion postoperatively, thus supporting previous reports. We could not demonstrate a definitive association between aprotinin administration and need for renal replacement therapy, but this might be partially attributed to the relatively low baseline renal risk of the present population. We also found that aprotinin administration was associated with a significantly increased risk of late mortality. Although aprotinin administration was associated with reduced incidence of red blood cell transfusion in the original sample (Table [S2](#jah32950-sup-0001){ref-type="supplementary-material"}), this association was no longer present after matching, which also accounted for participating centers. This observation suggests that in the ART, different transfusion policies, rather than aprotinin itself, might have influenced red blood cell transfusion exposure.

The main limitations of the present analyses are obviously the nonrandomized comparison (despite the close matching in the propensity‐scored patients) and the few outcome events, with consequently wide CIs. Despite PS modeling, we cannot exclude a residual selection bias based on unmeasured or unmeasurable characteristics. Another limitation is that the exact dose of aprotinin administered was not collected and, therefore, a dose‐response association cannot be excluded. However, a previous meta‐analysis did not find any association between dose and adverse events.[21](#jah32950-bib-0021){ref-type="ref"}

In conclusion, we found that the use of aprotinin was associated with an excess of early death and this also translated into an increased cardiac‐related mortality at 5 years. Aprotinin is currently offered to many patients undergoing CABG, and the present analysis supports the hypothesis that aprotinin use might be associated with an increase in avoidable deaths. Therefore, a word of caution should be exercised by local authorities on the liberal use of aprotinin during isolated CABG before stronger evidence of its safety profile will be available.
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[^1]: A complete list of the ART (Arterial Revascularization Trial) Investigators can be found in the Appendix at the end of the article.
